NasdaqGM:ADMABiotechs
FDA-Approved Yield Boost For ASCENIV Might Change The Case For Investing In ADMA Biologics (ADMA)
ADMA Biologics recently reported strong 2025 performance driven by higher demand for its immune globulin therapy ASCENIV, alongside improved payer coverage and confidence in long-term plasma supply that together provide clearer visibility into 2026 revenue acceleration.
The FDA’s approval of a yield-enhancement manufacturing process is particularly important, as it is expected to lift production efficiency while supporting higher margins and longer-term capital return efforts.
Now we’ll...